H.C. Wainwright Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $30

H.C. Wainwright analyst Ram Selvaraju maintains $Annovis Bio(ANVS.US)$ with a buy rating, and maintains the target price at $30.According to TipRanks data, the analyst has a success rate of 43.6%

Moomoo NewsJul 17 12:38 ET · Ratings

Buy Rating Affirmed for Annovis Bio Amidst Promising Drug Developments and Strategic Team Expansion

TipRanksJul 17 12:27 ET

Express News | HC Wainwright & Co. Reiterates Buy on Annovis Bio, Maintains $30 Price Target

BenzingaJul 17 06:35 ET

Annovis Bio Says US FDA Approved Use of Neurodegeneration Drug Buntanetap in Crystalline Form

Annovis Bio (ANVS) said Tuesday that the US Food and Drug Administration has granted the company approval to use a new crystalline form of its neurodegeneration drug buntanetap in future clinical

MT NewswiresJul 16 08:39 ET

Express News | Annovis Bio Granted FDA Approval To Transition To New Crystal Form Of Buntanetap

BenzingaJul 16 08:00 ET

Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap

Tue, 16 Jul 2024MALVERN, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug

Annovis BioJul 16 00:00 ET